Eli Lilly Advisor Reduces Stake by Over Half

Richard Bernstein Advisors LLC sells 8,397 shares of pharmaceutical giant Eli Lilly and Company

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

Richard Bernstein Advisors LLC, an institutional investor, has reduced its holdings in Eli Lilly and Company (NYSE:LLY) by 55.8% in the third quarter, according to a recent SEC filing. The firm now owns 6,648 shares of the company's stock, down from 15,045 shares previously.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, so changes in institutional ownership can signal shifts in investor sentiment around the stock. This reduction by Richard Bernstein Advisors, a respected investment management firm, is notable and may indicate broader trends in the healthcare sector.

The details

According to the filing, Richard Bernstein Advisors sold 8,397 shares of Eli Lilly in the third quarter, reducing its total position to 6,648 shares. The firm's holdings in Eli Lilly were valued at $5,072,000 as of the most recent filing.

  • Richard Bernstein Advisors reduced its Eli Lilly stake in the third quarter of 2026.

The players

Richard Bernstein Advisors LLC

An institutional investment management firm that has reduced its holdings in pharmaceutical company Eli Lilly and Company.

Eli Lilly and Company

A global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana.

Got photos? Submit your photos here. ›

The takeaway

This reduction in Eli Lilly holdings by a major institutional investor could signal broader shifts in sentiment around the pharmaceutical sector, though the specific reasons behind the portfolio change are not entirely clear from the limited information provided.